Skip to Content

Bausch Health Companies Inc BHC

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

No-Moat Bausch Not Quite Back to Normal, but Decent Q4 Shows Recovery Well Underway; Maintaining FVE

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Bausch Health had a decent end to the year, slightly exceeding our expectations, and the company remains on a gradual path to recovery from the pandemic lows of mid-2020. We are maintaining our $23 fair value estimate and no-moat rating, though we may make minor adjustments to our valuation when full annual data is published later this week.

Read Full Analysis

Company Profile

Business Description

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in four segments: Bausch+Lomb and international (55% of revenue), Salix pharmaceuticals (25%), ortho dermatology (6%), and diversified products (14%), and approximately 13% of revenue is attributable to non-U.S. markets. Bausch is the market leader in consumer visioncare in India and China, and the fourth- largest visioncare company by sales in the United States.

Contact
2150 Saint Elzear Boulvard West
Laval, QC, H7L 4A8, Canada
T +1 514 744-6792
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type
Employees 21,600

Related